Considering the importance of imatinib, an ABL tyrosine kinase inhibitor used in the treatment of BCR/ABL-positive CML, inhibitors against other tyrosine kinases are likely to become increasingly important for the treatment of AML [19,23]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.